SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as a community-driven token focused on cannabis culture and natural wellness. Discussions highlight its mission to challenge the pharmaceutical industry and promote the plant's benefits. The community emphasizes its organic growth, freedom, and aim to bring balance to the digital world.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital ($APLD) is trending after its earnings call, where the company highlighted substantial revenue growth and potential new hyperscaler partnerships, fueling optimism about its future in AI data centers. The community is buzzing about potential price target upgrades and the possibility of a short squeeze, while some traders are closely monitoring overnight trading activity and potential profit-taking strategies. Despite discussions around debt and valuation, the overall sentiment leans bullish, driven by the company's expansion plans and its position in the growing AI sector.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community anticipates a potential ETF and discusses key resistance levels that need to be broken for a significant upward move. Some traders are pointing to technical formations suggesting a possible breakout, while others express concerns about LTC's historical underperformance compared to other cryptocurrencies. The conversation also includes speculation on how the broader market and potential government shutdowns could impact Litecoin's price.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ (LAES) is trending due to a new strategic partnership to develop quantum-resistant chips for U.S. defense applications, sparking excitement about potential government contracts. Community members are actively discussing the company's growth potential and comparing it to other quantum computing stocks. Some investors believe LAES is significantly undervalued and poised for a substantial run.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending due to renewed interest in privacy coins and speculation around potential use cases amidst growing concerns about financial surveillance; the community is actively discussing price targets and the cryptocurrency's long-term potential, drawing comparisons to Bitcoin's fundamentals and previous market cycles. Bullish sentiment seems to be building around ZEC's privacy features and fixed supply, with some believing it could reach new all-time highs if the current movement continues.

Spell Token

Spell Token is gaining attention, with community members actively discussing potential catalysts and expressing hopes for a significant price surge. Some are focused on accumulating more tokens, while others are sharing long-term price predictions and potential targets. Discussions also include the possibility of new developments and partnerships.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound is trending as the community discusses its potential for a breakout, citing its low token supply and undervalued status relative to Total Value Locked (TVL). Some investors express frustration with its lagging performance compared to other cryptocurrencies, while others point to upcoming catalysts and governance updates as potential drivers for future growth. Bullish sentiment revolves around its strong fundamentals and the expectation of a significant upward move.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending due to increased community discussion around its potential short squeeze and transition into AI/HPC data centers, with some traders comparing it to peers like APLD and IREN. The community highlights TeraWulf's attractive entry point, high short interest, and backing from Google, fueling speculation about significant upward movement. Chatter suggests that TeraWulf is playing catch up with other tickers in the AI/HPC sector.

GSR III Acquisition Corp engages in the merger, share exchange, asset acquisition, share purchase or reorganization with one or more businesses. The company was founded on May 10, 2023 and is headquartered in Austin, Texas.

GSR III Acquisition Corp. - Ordinary Shares- Class A

GSR III Acquisition Corp. Ordinary Shares

GSRT is trending due to the upcoming ticker change to NKLR, representing Terra Innovatum, with the merger vote scheduled for October 7th. The community anticipates heightened volume and volatility as the company becomes a publicly traded nuclear developer, potentially making it the next big play in the sector. Some are drawing comparisons to OKLO and anticipating significant gains, while others are wary of the volatility associated with SPAC mergers.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. ($INOD) is trending due to bullish technical analysis and anticipation surrounding the upcoming Gen AI Summit and Q3 earnings report. The community is actively discussing potential new contracts or a possible acquisition, fueled by recent institutional buying and a lack of insider selling. Many see $INOD as undervalued in the growing AI data market, with some speculating about significant long-term growth and potential takeover targets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Verastem (VSTM) Upgraded to Buy: Here's What You Should Know

Verastem (VSTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates

Verastem (VSTM) delivered earnings and revenue surprises of +54.12% and -86.36%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates

Gossamer Bio (GOSS) delivered earnings and revenue surprises of +5.56% and +155.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline

Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?  

Shares of Verastem Oncology (VSTM) dropped 19% on Monday despite the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-updated-data-partner-genfleet">announcing</a> positive updated data from the dose escalation phase of its trial for cancer therapy GFH375, conducted by its partner, GenFleet Therapeutics.In a study in China, GFH375, also known as VS-7375 in the U.S., demonstrated an overall response rate of 52% in patients with pancreatic ductal adenocarcinoma and a response rate of 42% in those with non-small cell lung cancer, the company stated.Verastem stated that data from its partner supports the advancement of its clinical program for VS-7375 in the U.S., which is slated to start in mid-2025.The company is activating sites in the U.S. for VS-7375 to begin enrollment in the trial. The study has the potential to expand globally and will evaluate the safety and efficacy of VS-7375 in patients with advanced, KRAS G12D-mutant solid tumors.The KRAS G12D mutation, a genetic alteration in the KRAS gene, is common in various cancers, particularly pancreatic cancer, colorectal cancer, and lung adenocarcinoma.As part of the collaboration between Verastem and GenFleet, Verastem has development and commercialization rights for the cancer therapy outside the GenFleet markets of mainland China, Hong Kong, Macau, and Taiwan.On Stocktwits, retail sentiment around Verastem rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_12_42_50_PM_png_7c68caaf50.webp" alt="VSTM's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 2, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>VSTM's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock could be tanking owing to the Chinese partnership.<stembedurl>https://stocktwits.com/Universaal/message/616509493</stembedurl>According to data from Koyfin, all of the nine analysts covering the stock rate it ‘Buy’ or higher. The stock has an average price target of $15.75, representing an upside of over 150%.<a href="https://stocktwits.com/symbol/VSTM">VSTM stock</a> is down by 6% this year but up by about 55% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-s-push-toward-fully-automated-ads-to-reportedly-debut-by-year-end/chkY2oMRbHJ">Meta’s Push Toward Fully Automated Ads To Reportedly Debut By Year-End</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish

In a study conducted in China, GFH375, also known as VS-7375 in the U.S., showed an overall response rate of 52% in patients with pancreatic ductal adenocarcinoma and 42% in those with non-small cell lung cancer.

Equity

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

The U.S. Food and Drug Administration on Thursday granted accelerated approval to Verastem Oncology’s (VSTM) combination therapy for adult patients with a particular type of ovarian cancer.The combination of Avutometinib capsules and Defactinib tablets, under the brand name Avmapki Fakzynja Co-pack, can now be used to <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low">treat</a> patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior treatment.LGSOC is a rare ovarian cancer which is highly recurrent and less sensitive to chemotherapy compared to high-grade serous ovarian cancer. Approximately 6,000-8,000 women in the U.S. and 80,000 worldwide are living with this disease, as per Verastem.Avmapki Fakzynja Co-pack is the first and only FDA-approved medicine for this disease, Verastem said, while adding that the oral medicine pack is expected to be available for adult patients in the U.S. in one week.The FDA previously granted priority review to Verastem’s drug application and also designated it a breakthrough therapy and orphan drug.Late last month, the company announced a $75 million private placement. The proceeds would be used to fund the launch of the combination therapy, among other things. &nbsp;On Stocktwits, retail sentiment around Verastem rose from ‘neutral’ to ‘bullish’ over the past 24 hours while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:626/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_08_at_1_01_06_PM_png_213d5d0710.webp" alt="VSTM's Sentiment Meter and Message Volume as of 1:00 p.m. ET on May 8, 2025 | Source: Stocktwits" width="626" height="63"><figcaption>VSTM's Sentiment Meter and Message Volume as of 1:00 p.m. ET on May 8, 2025 | Source: Stocktwits</figcaption></figure>The stock is trading 3% higher on Thursday afternoon after a trading halt.&nbsp;<a href="https://stocktwits.com/symbol/VSTM">VSTM stock</a> has gained by about 6% this year but has fallen by about 39% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/viatris-reports-q1-earnings-above-estimates/chifqcaRbk1">Viatris Q1 Earnings Exceed Wall Street Expectations, Company Raises Full-Year Profit Outlook: Retail’s Positive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased

The combination of Avutometinib capsules and Defactinib tablets, under the brand name Avmapki Fakzynja Co-pack, can now be used to treat patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior treatment.

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Womens Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple oral and poster...

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team will...

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

VSTM
Verastem Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VSTM News

VSTMVerastem Inc